Medical Device and Diagnostics IP Toolkit: Claims, Regulatory Timing, and Aftermarket Control

By Casey Scott McKay · 2026-07-11

Medical device and diagnostic intellectual property runs on two clocks that rarely align, and most portfolio failures in the sector come from treating them as one. This toolkit collects the regimes. It works the eligibility problem that hit diagnostic method claims hardest, the claim drafting that survives it, and the filing timing that has to be set against regulatory submissions rather than against product launch. It then covers the safe harbour research exemption, design and trade dress protection for instruments, the consumables and servicing aftermarket where the commercial value concentrates, software as a medical device, promotional claim constraints that no marketing team expects, and the procurement layer that decides adoption.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 11 July 2026 - Updated 12 August 2026 | Casey Scott McKay - marksy.us

Summary. Medical device and diagnostic intellectual property runs on two clocks that rarely align, and most portfolio failures in the sector come from treating them as one. This toolkit collects the regimes. It works the eligibility problem that hit diagnostic method claims hardest, the claim drafting that survives it, and the filing timing that has to be set against regulatory submissions rather than against product launch. It then covers the safe harbour research exemption, design and trade dress protection for instruments, the consumables and servicing aftermarket where the commercial value concentrates, software as a medical device, promotional claim constraints that no marketing team expects, and the procurement layer that decides adoption.

Keywords: medical device IP toolkit · diagnostic method eligibility · Mayo and Alice · claim drafting for devices · regulatory timing · safe harbour research exemption · 510k predicate disclosure · design patents on devices · trade dress in instruments · consumables and reagents · parts pairing in devices · servicing restrictions · software as a medical device · clinical trial confidentiality · labelling and promotional claims · off label promotion · hospital procurement · group purchasing · reprocessing single use devices · international filing

Start Here

A device company asks when to file, and the honest answer is that the question has two deadlines and they are set by different institutions.

The intellectual property clock runs from conception through disclosure to the statutory bars in 35 U.S.C. § 102, and it rewards early filing.

The regulatory clock runs from bench testing through clinical evaluation to submission and clearance or approval, and it takes years during which the invention must be described to investigators, ethics committees, regulators, and sometimes the public.

They do not align, and the failure mode is consistent: a company files at product launch, having disclosed the invention across three years of clinical work and a public trial registration, and discovers that the foreign rights are gone and the domestic position is narrower than expected.

Underneath that sits a second structural problem. Diagnostic methods — the core intellectual property of an entire industry segment — occupy the hardest ground in eligibility doctrine, and claims that would have issued comfortably two decades ago now fail at the threshold.

And a third. The commercial value in most device businesses is not in the instrument. It is in the consumables, the reagents, the cartridges, and the service contract — an aftermarket whose control mechanisms attract the same scrutiny as any other, with a safety overlay that is partly genuine and partly convenient.

The Eligibility Problem

35 U.S.C. § 101 and the two-step framework built on it are the defining constraint on diagnostic claims.

Mayo Collaborative Services v. Prometheus Laboratories held claims to a method of optimising drug dosage by measuring a metabolite and correlating the level with a need to adjust dosage ineligible, on the reasoning that the correlation was a law of nature and the additional steps were conventional.

Alice Corp. v. CLS Bank International generalised the framework: determine whether the claim is directed to a patent-ineligible concept, and if so, whether the elements individually and as an ordered combination transform it into a patent-eligible application.

Association for Molecular Pathology v. Myriad Genetics held isolated naturally occurring DNA ineligible as a product of nature while complementary DNA remained eligible.

Ariosa Diagnostics v. Sequenom applied Mayo to a genuinely significant discovery — the presence of cell-free foetal DNA in maternal plasma — and held the claims ineligible because the detection steps were conventional. The concurrence's discomfort with that outcome is the clearest statement of the doctrine's cost.

Athena Diagnostics v. Mayo Collaborative Services confirmed the position and produced an unusual set of separate opinions on denial of rehearing en banc, in which judges across the court described the law as unworkable while considering themselves bound.

The practical drafting consequences.

Claim the apparatus, not only the method. A device, an assay system, a cartridge, or a kit is a machine or a manufacture, and the eligibility analysis is materially easier.

Claim a method of treatment where one exists. Vanda Pharmaceuticals v. West-Ward Pharmaceuticals held claims to a method of treating a condition by administering a specific dose based on a genotype eligible, distinguishing Mayo on the basis that the claim was to a treatment rather than to a diagnostic correlation. The line between them is thin and it is the most important line in the field.

Claim unconventional technique steps specifically. Where the detection or sample preparation involves genuinely new technique, claim it in detail, because the second step turns on whether the additional elements are conventional.

Avoid claiming the correlation. A claim whose inventive contribution is the discovery of a relationship will fail, however valuable the discovery.

And build the trade secret position in parallel, because the algorithm, the reference database, the assay optimisation, and the interpretation rules may be more defensible as trade secrets than as claims that cannot issue.

Regulatory Timing

Set the filing calendar against the regulatory calendar, not against the commercial one.

Disclosure events that start clocks. Investigator brochures and study protocols distributed to sites. Ethics committee submissions. Public clinical trial registration, which is mandatory and which publishes a structured description. Conference abstracts and posters, which precede publication by months. Regulatory submissions, portions of which may become public on clearance or approval. And the 35 U.S.C. § 102(b) grace period, which is domestic only and short.

Which means the practical rule is to file before the first site receives a protocol. Everything after that is a race against a disclosure the company itself made.

Then the predicate disclosure problem specific to devices. A submission relying on substantial equivalence to a predicate device discloses the comparison, and clearance summaries are published. That publication is prior art against the company's later filings and against everyone else's — and it is a source of competitive intelligence the company supplied.

The safe harbour is broader than practitioners expect. 35 U.S.C. § 271(e)(1) exempts making, using, offering to sell, selling, or importing a patented invention solely for uses reasonably related to the development and submission of information under a federal law regulating drugs or biological products.

Eli Lilly v. Medtronic held the safe harbour applies to medical devices, not only to drugs.

Merck KGaA v. Integra Lifesciences I construed it broadly, covering preclinical work where there was a reasonable basis to believe the compound might be the subject of a submission and the experiments would produce relevant information.

Which means a competitor may lawfully use a patented device or method in developing its own regulatory submission, and that is a substantial gap in the exclusivity a device patent provides. Portfolio strategy has to account for it: the patent protects the market, not the development.

And note the reverse. A company doing its own development work using a competitor's patented technology is likely covered, which is worth knowing before assuming a freedom-to-operate problem exists.

Design, Trade Dress, and the Instrument

Devices are designed objects and the design is protectable, and this is underused in a sector focused on utility claims.

35 U.S.C. § 171 design patents cover the ornamental appearance of an instrument, a handpiece, a cartridge, a housing, or a display interface. Infringement is assessed by the ordinary observer standard confirmed in Egyptian Goddess v. Swisa, and 35 U.S.C. § 289 permits recovery of the infringer's total profits from the article of manufacture.

LKQ Corp. v. GM Global Technology Operations made design patents more vulnerable on obviousness by replacing the rigid framework with a flexible approach, which matters to both sides of a device aftermarket dispute.

Trade dress under 15 U.S.C. § 1125(a) protects instrument appearance and packaging, subject to two constraints that bite hard here. Wal-Mart Stores v. Samara Brothers requires secondary meaning for product design, and TrafFix Devices v. Marketing Displays bars protection for functional features — and in a regulated device, a great many features are dictated by the standard, the ergonomics, or the sterilisation method.

Which leaves the protectable expression in colour schemes, housing profiles, display layouts, and the packaging — none trivial in a market where clinicians identify products visually under time pressure.

Copyright covers the software, the user interface graphics, the instructions for use, the training materials, and the documentation, and registration is cheap and worth doing across the whole set.

The Aftermarket

This is where the money is, and where the intellectual property strategy meets its regulatory and antitrust limits.

Consumables and reagents. Cartridges, test strips, electrodes, tubing sets, and assay reagents generate recurring revenue and are the natural target of third-party supply.

The doctrine mostly favours the third party. Aro Manufacturing v. Convertible Top Replacement permits a purchaser to replace worn components, and Impression Products v. Lexmark International holds that a patentee's sale exhausts all patent rights in the item regardless of any post-sale restriction.

So the control comes from three other places. A utility patent claiming the consumable itself rather than the system. A design patent on the consumable's form. And authentication — a chip in the cartridge that the instrument checks.

Authentication moves the analysis to 17 U.S.C. § 1201, and the circuit split between Chamberlain Group v. Skylink Technologies and MDY Industries v. Blizzard Entertainment is unresolved. The triennial rulemaking has granted repair exemptions covering medical devices in varying formulations, and they expire on a three-year cycle.

Servicing restrictions carry a genuine regulatory overlay and a contested one. Servicing can affect a device's compliance status, and manufacturers argue that independent service threatens safety. Hospital biomedical engineering departments and independent service organisations argue the safety case is thin and the commercial motive is not.

17 U.S.C. § 117 matters directly here, permitting a person maintaining or repairing a machine to make a copy made solely by activating the machine, used for no other purpose, and destroyed on completion. It was enacted for exactly this dispute.

And the antitrust exposure is real. Eastman Kodak v. Image Technical Services held that a single brand's parts and service can constitute relevant markets, and the device sector has the information and switching asymmetries the decision described. Verizon Communications v. Trinko narrows refusal-to-deal claims and does not eliminate them.

Reprocessing of single-use devices is a regulated activity with its own clearance pathway, and a manufacturer's single-use labelling does not by itself prevent it — Jazz Photo v. International Trade Commission makes the same point in a different sector.

15 U.S.C. § 2302(c) prohibits conditioning a written warranty on the use of branded articles or services, and device warranty language breaches it with some regularity.

Software as a Medical Device

Software that performs a medical function is a device, and it sits at the intersection of every difficult question in this toolkit.

Eligibility. An algorithm that computes a clinical result faces the Alice framework directly, and claims drafted as data processing steps fail. Claims tied to a specific technical implementation, to a novel sensing arrangement, or to a treatment step fare better.

Copyright covers the code and the interface, subject to the ordinary limits on functional expression.

Trade secret frequently carries more of the value than either, particularly for models, training data, reference ranges, and interpretation rules — none of which need be disclosed.

Which conflicts with regulatory transparency expectations and with clinical demands for explainability. A model whose competitive advantage depends on opacity may not be adoptable.

Updates create a version problem. A device changes when its software changes, which raises regulatory questions about whether the change requires a new submission, and intellectual property questions about whether the improvement is separately protectable and separately owned where a development partner contributed.

And the technology contract analysis applies to any cloud component: data rights, exit and portability, service levels, and what happens to a hospital's data when the vendor relationship ends.

Claims, Labelling, and Promotion

What a device may be advertised to do is fixed by its clearance or approval, and this constrains marketing in ways the team rarely anticipates.

Promotion consistent with the labelling is the baseline. Claims beyond the cleared indications are off-label promotion and are regulated independently of any intellectual property question.

Comparative claims require substantiation to a standard the regulator and a competitor will both test, and 15 U.S.C. § 1125(a) supports a competitor false advertising claim that moves faster than a regulator will.

Lexmark International v. Static Control sets the zone of interests test for standing, and competitors in this sector do sue each other over performance and clinical claims.

Clinical evidence is the substantiation, which means marketing claims should be derived from the study endpoints rather than from a summary somebody wrote afterwards.

Brand names require regulatory review in some pathways, and a name cleared by trademark counsel may be refused on confusion-with-another-product grounds by a reviewer applying entirely different criteria. Run both clearances in parallel, using the name approval discipline.

And the instructions for use are simultaneously a regulatory document, a copyright work, a liability document, and a source of prior art. Treat them as all four.

Procurement, Which Decides Adoption

A device that cannot be bought is not sold, and hospital procurement operates on its own logic.

Group purchasing organisations aggregate demand and negotiate on behalf of member institutions, which means market access frequently depends on a contract with an intermediary rather than on the clinical merits.

Value analysis committees assess new products against clinical benefit, total cost, and workflow, and a superior device with a higher consumable cost may lose to an inferior one with a lower total.

Integration requirements — with electronic records, with laboratory information systems, with existing instrument fleets — can be decisive, and they raise interoperability questions where a competitor's interface is proprietary. The reverse engineering and interoperability discipline applies.

Standardisation contracts commit an institution to a single supplier for a category over a term, which is a legitimate purchasing practice and one that raises exclusion questions where the supplier's market position is strong.

And data ownership terms in the purchase agreement determine what the manufacturer may do with usage and outcome data generated by the device in the institution — increasingly the most valuable thing the transaction produces, and frequently unaddressed.

Portfolio Strategy by Business Model

The right portfolio differs sharply by how the business makes money.

Instrument-and-consumable businesses. The instrument is a delivery mechanism and the consumable is the product. File the strongest claims on the consumable itself — its composition, its structure, its interface with the instrument — because a claim to the system is exhausted by the instrument sale and reaches no replacement cartridge. Add a design patent on the consumable's form and an authentication decision made with the 17 U.S.C. § 1201 analysis in view rather than as an engineering choice.

Capital equipment businesses. Long product cycles, service revenue, and installed-base lock-in. The portfolio should cover the instrument architecture, the service tools, and the software, and the servicing position should be built on genuine safety substantiation rather than on assertion, because Kodak exposure is real and legislative attention to device servicing is rising.

Single-use device businesses. Reprocessing is a regulated activity with its own clearance pathway, and single-use labelling does not prevent it. Claims to the device itself and design patents on its form are what actually constrain a reprocessor, and Jazz Photo confirms that the manufacturer's characterisation does not decide the repair-versus-reconstruction question.

Diagnostic service laboratories. The test is performed in-house rather than sold, which means method claims are the only patent route and the Mayo framework makes them hard. Trade secret on the assay optimisation, the reference database, and the interpretation algorithm typically carries more value, and it survives disclosure obligations better than the alternative.

Software-only businesses. Copyright on the code, trade secret on the model and the data, and a narrow patent position on any genuinely technical implementation. The technology contract architecture — data rights, exit, service levels — carries as much commercial weight as the intellectual property.

Component and subassembly suppliers. Selling into device manufacturers, whose regulatory obligations flow up the supply chain. The intellectual property questions are ordinary; the contract questions about change control, notification obligations, and continuity of supply are not, because a supplier's unilateral design change can invalidate a customer's clearance.

Combination products. Device plus drug or biologic, with two regulatory regimes and two exclusivity architectures. The device pathway offers no data exclusivity equivalent, which means the patent position carries the whole burden on the device side.

Diligence Questions

Twelve questions surface most of the problems in a device or diagnostic transaction.

When was the first filing relative to the first site protocol? If the protocol went out first, foreign rights are probably gone and the domestic grace period may have expired.

Is the public trial registration entry prior art against anything the company later filed? It is structured, dated, and public, and it describes the intervention.

Do the diagnostic method claims survive Mayo and Alice? Read the claims, not the abstract. A claim whose inventive contribution is a correlation will not hold.

Are there apparatus, kit, or method-of-treatment claims as well? If the portfolio is method claims only, it is more fragile than its size suggests.

What did the clearance summary disclose? It is published, it is prior art, and it is competitive intelligence the company supplied.

Is the safe harbour exposure understood? 35 U.S.C. § 271(e)(1) as construed in Eli Lilly v. Medtronic and Merck KGaA v. Integra means competitors may lawfully use the patented technology in their own development. The patent protects the market, not the development, and a valuation assuming otherwise is wrong.

Who owns the software, and who wrote it? Contractors and development partners own their contributions absent a written assignment, and device software is frequently written by both.

Who owns the regulatory file? In a contract manufacturing or development relationship this is frequently unaddressed, and it determines whether the company can move manufacturers.

What does the consumable authentication do, and what happens if it is defeated? This is the 17 U.S.C. § 1201 question and it decides whether the aftermarket is defensible.

Do the warranty terms condition coverage on branded consumables or authorised service? 15 U.S.C. § 2302(c) prohibits it, and the language survives in manuals nobody reviews.

What do the hospital purchase agreements say about data? Usage and outcome data generated in the institution is frequently the most valuable output of the relationship and frequently unaddressed.

And are the promotional claims traceable to study endpoints? A comparative claim derived from a marketing summary rather than from the data is both a regulatory exposure and a false advertising target under Lexmark.

Common Errors

Filing at product launch. By then the protocol, the registration, the abstracts, and possibly the clearance summary have all disclosed the invention. File before the first site receives a protocol.

A portfolio of method claims only. After Mayo and Ariosa, diagnostic method claims are the weakest asset in the field. Apparatus, kit, and treatment claims carry the portfolio.

Claiming the correlation. A claim whose contribution is the discovery of a relationship fails however significant the discovery, which is the whole lesson of Ariosa and of the separate opinions in Athena.

Assuming a patent blocks a competitor's development. 35 U.S.C. § 271(e)(1) covers it, broadly, per Merck KGaA v. Integra.

Building the aftermarket on post-sale restrictions. Impression Products stripped them of patent force. The consumable claim, the design patent, and the authentication are what remain.

Treating authentication as an engineering decision. It is the 17 U.S.C. § 1201 decision, it determines the aftermarket position, and it should be made with the circuit split and the triennial exemption cycle in view.

Asserting safety without substantiation. A servicing restriction described as safety-based, with no documented failure mode, reads as pretext and undermines every other position in front of a regulator or a legislature.

Warranty conditioning. 15 U.S.C. § 2302(c) prohibits it, the language survives in manuals, and the fix takes five minutes.

Ignoring design protection. Instruments are designed objects, 35 U.S.C. § 289 total profits is available, and the sector files design patents at a fraction of the rate its exposure would justify.

And running trademark clearance separately from regulatory name review. A name cleared by counsel may be refused by a reviewer applying confusion criteria of a different kind. Run both in parallel.

Drafting for Eligibility

Since eligibility is the binding constraint, the drafting deserves its own treatment.

Draft a claim set, not a claim. Apparatus, system, kit, method of detection, method of treatment, and computer-readable medium — each with a different eligibility profile, and the set survives what any single claim would not.

For apparatus claims, recite the physical elements and their arrangement, including any element that is genuinely non-standard. A cartridge with a specific fluidic architecture is a manufacture and the framework does not reach it in the way it reaches a method.

For method-of-treatment claims, follow Vanda: recite administering a specific agent at a specific dose to a patient identified by a specific criterion. The claim must be to treating, not to determining that treatment is indicated, and that distinction is the entire margin.

For detection methods, recite the technique in detail where the technique is new. The second step of the Alice framework asks whether the additional elements are conventional, and a genuinely novel sample preparation, amplification, or detection step is the answer.

Avoid claim language that recites a correlation as the point. "Determining X and correlating X with Y" is the shape that fails. "Performing technique Z on a sample to produce measurement X" is the shape that has a chance.

Support the specification for the 35 U.S.C. § 112 analysis as well. A claim that survives eligibility can still fail on written description or enablement, particularly where it is drafted functionally to capture future implementations.

Consider continuation practice deliberately. Eligibility law in this area has moved and may move again, and keeping a continuation pending allows claims to be drafted against the doctrine as it stands rather than as it stood at filing.

And consider whether to file at all. For some diagnostic inventions the honest answer is that no obtainable claim would be both eligible and commercially meaningful, and the disclosure required by a filing is a gift to competitors. Trade secret protection on the assay and the interpretation, with no publication, is sometimes the better position — and it is a decision to be made deliberately rather than by default.

The Two Clocks, Sequenced

A worked timeline for a device programme, working from the regulatory schedule backwards.

Concept and bench work. File a provisional on anything with a plausible claim, cheaply and often. This is before any external disclosure and it is the least constrained moment in the programme.

Design freeze. File the design patent applications on the instrument, the handpiece, the cartridge, and the interface. Disclosure has not happened; after the trade show or the investor deck it has.

Before the first site protocol goes out. File the utility applications. This is the hard deadline, and it precedes everything the regulatory calendar contains.

Trial registration. A structured public description of the intervention. Everything after this is public.

Clinical conduct. Investigator brochures, ethics submissions, site training materials, and interim analyses circulate. Each is a disclosure to a defined group and several are not confidential in practice.

Conference presentation. Abstracts publish months before the meeting. Treat abstract submission as the disclosure date, not the presentation.

Publication. Journal submission and publication, with the sponsor's filing window secured by the publication timing provisions in the clinical study agreement — which is why those provisions matter more than anything else in that document.

Regulatory submission. Portions become public on clearance or approval, and the clearance summary is prior art.

Clearance or approval. Labelling is fixed, promotional claims are constrained to it, and the brand name has cleared or not.

Launch. Trade dress evidence collection begins, because Wal-Mart Stores v. Samara Brothers requires secondary meaning and it accrues from launch or not at all.

Post-market. Software updates raise version and submission questions; usage data accumulates under whatever the purchase agreements said; and the consumable aftermarket begins attracting third parties around the point the installed base becomes worth serving.

Read the sequence and one thing stands out. Every intellectual property deadline in the programme falls before the first clinical site is opened, and every commercial validation falls afterwards. A company that waits for validation before filing has waited too long by years, and no amount of later diligence recovers it.

Cadence

Annually, six items.

Claim set review against current eligibility law. The doctrine in this area has moved and continuations pending allow claims to be drafted against it as it stands. A portfolio reviewed once at filing is a portfolio drafted against a superseded standard.

Design patent maintenance decisions. Prune instruments no longer sold; add filings for the current generation.

Trade dress evidence collection. Advertising spend, unsolicited coverage, sales volumes, look-for advertising, and any instances of actual confusion, per product line.

Circumvention exemption check. The triennial cycle runs on its own schedule, renewal is not automatic, and an authentication strategy resting on a lapsed rule has changed without anyone noticing.

Warranty and service terms audit. Against 15 U.S.C. § 2302(c), and against whatever the safety substantiation actually supports.

Promotional claim traceability. Every comparative and performance claim in current materials, traced to a study endpoint or withdrawn.

Per programme, three more.

Confirm the filing preceded the protocol for every active development programme, and record the dates.

Confirm software ownership for every module, including contractor and partner contributions, with assignments in the file.

And confirm regulatory file ownership in every contract manufacturing and development relationship, because it determines whether the company can move suppliers and it is the provision most often absent.

A Closing Note

This sector has an unusual asymmetry. The regulatory pathway is slow, expensive, and thoroughly documented; the intellectual property deadlines are fast, cheap to meet, and almost entirely undocumented in the programme plan.

Which means the failures are systematic rather than accidental. A company with a rigorous submission process and no filing trigger tied to it will file late every time, on every programme, for the same structural reason.

The fix is one line in the programme plan. Utility filings before the first site protocol; design filings at design freeze. Two dates, tied to milestones the programme already tracks.

Everything else in this toolkit is downstream of those two dates, and none of it can compensate for missing them.

Adjacent Regimes That Bind Independently

Several frameworks constrain a device programme without touching intellectual property at all, and a portfolio strategy built without them is incomplete.

Clinical study agreements. Publication timing, data ownership, ownership of inventions made by investigators, and the sponsor's filing window. The invention provisions in these agreements are the most consequential and the least negotiated.

Specimen and biobank terms. Material received for assay development carries downstream ownership and consent limitations that follow into anything developed from it, and a diagnostic built on specimens obtained under research consent may not be commercialisable on those terms.

Human subjects and privacy. Patient data generated by a device is health information, and the obligations attaching to it are separate from and stricter than the ordinary state privacy statutes analysis, and stricter again where biometric identifiers are processed.

Cybersecurity obligations for connected devices, which are now a submission requirement in several pathways and which interact with the servicing and authentication questions above — a device hardened against unauthorised access is also a device hardened against independent service.

Export controls. Certain device and software technologies are controlled, and the export analysis reaches disclosure to foreign nationals within the company's own facilities.

Standards participation. Interface and interoperability standards for laboratory instruments and clinical systems carry disclosure and licensing commitments, and a company that contributed technology to a standard may have granted more than it intended.

Reimbursement. A cleared device with no reimbursement code is a device nobody buys, and the coding pathway runs on its own timetable with its own evidence requirements — which frequently means additional clinical work after clearance and further disclosure.

And product liability, which shapes the labelling, the instructions for use, the training materials, and the post-market surveillance obligations, all of which are also copyright works, regulatory documents, and prior art.

Enforcement in This Sector

Device patent litigation has three features worth knowing before commencing.

The defendant is usually a competitor rather than a customer. Suing hospitals is commercially impossible, which means the enforcement target is the manufacturer of the competing device or the supplier of the third-party consumable, and the claim has to reach them rather than the end user.

Induced infringement matters more than direct. Where the claim is a method performed by a clinician, the manufacturer's liability runs through 35 U.S.C. § 271(b) inducement, which requires knowledge and intent — and which makes the instructions for use, the training materials, and the marketing claims the central evidence.

Which is a reason to read a competitor's instructions for use carefully. They frequently instruct the very steps the method claim recites.

Injunctive relief is complicated by patient impact. eBay v. MercExchange requires the four-factor analysis, and the public interest factor carries unusual weight where an injunction would remove a device clinicians rely on. Expect a royalty rather than an exclusion in a contested case involving a clinically established product.

Damages under 35 U.S.C. § 284 turn on the consumable stream rather than the instrument in most business models, which makes the royalty base and the apportionment analysis the substance of the case.

Enhanced damages under the Halo Electronics v. Pulse Electronics standard require egregiousness, and a competitor operating in reliance on the 35 U.S.C. § 271(e)(1) safe harbour during development is not a candidate.

And the section 337 route is available and underused for imported devices and consumables, with a schedule federal litigation cannot match and exclusion orders that reach unnamed parties.

Post-grant challenge is the standard response, and a device patent asserted against a well-resourced competitor should be assumed to face an inter partes review petition. That is a reason to prosecute with the eventual challenge in mind rather than to maximise allowance rate.

One more enforcement observation. The strongest device cases are frequently not patent cases at all. A competitor whose comparative clinical claim is unsupported, or whose consumable is marketed as equivalent when the performance data says otherwise, is exposed under 15 U.S.C. § 1125(a) on a timetable and an evidentiary burden a patent case cannot match — and the remedy sought is the same commercial outcome.

Consider that route first in any dispute where the competitor's claims are doing the commercial damage rather than the competitor's technology.

It is faster, cheaper, and it survives an eligibility challenge the patent claims may not.

A Suggested Reading Path

Start with the doctrine in The Device and the Approval.

Then the portfolio operations in Building a Medical Device IP Portfolio.

Then the audit in the medical device checklist.

For the aftermarket analysis in general form, read The Part That Broke and the Aftermarket, Repair, and Spare Parts IP Toolkit.

For the eligibility framework, the Patent Fundamentals Toolkit.

For the life sciences adjacency, the Life Sciences Patent Toolkit, noting that the device pathway differs substantially from the drug pathway.

For design protection, the Design Patent Toolkit and the Layered Design Protection Toolkit.

And for the trade secret layer that carries what claims cannot, the confidentiality discipline.

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 101 | Patentable subject matter | | 35 U.S.C. § 102 | Novelty; statutory bars | | 35 U.S.C. § 103 | Obviousness | | 35 U.S.C. § 112 | Written description; enablement | | 35 U.S.C. § 171 | Design patents | | 35 U.S.C. § 271 | Infringement; safe harbour | | 35 U.S.C. § 283 | Injunctions | | 35 U.S.C. § 284 | Damages | | 35 U.S.C. § 289 | Total profits remedy | | 17 U.S.C. § 117 | Maintenance and repair copies | | 17 U.S.C. § 1201 | Circumvention; exemptions | | 15 U.S.C. § 1125 | False designation; trade dress | | 15 U.S.C. § 2302 | Warranty anti-tying provision | | Mayo Collaborative Services v. Prometheus Laboratories | Natural law; conventional steps | | Alice Corp. v. CLS Bank International | Two-step eligibility framework | | Association for Molecular Pathology v. Myriad Genetics | Isolated DNA; cDNA | | Ariosa Diagnostics v. Sequenom | Diagnostic claims ineligible | | Athena Diagnostics v. Mayo Collaborative Services | Diagnostic eligibility confirmed | | Vanda Pharmaceuticals v. West-Ward Pharmaceuticals | Method of treatment eligible | | Eli Lilly v. Medtronic | Safe harbour covers devices | | Merck KGaA v. Integra Lifesciences I | Safe harbour construed broadly | | Egyptian Goddess v. Swisa | Ordinary observer test | | LKQ Corp. v. GM Global Technology Operations | Design patent obviousness | | Wal-Mart Stores v. Samara Brothers | Product design; secondary meaning | | TrafFix Devices v. Marketing Displays | Functionality | | Impression Products v. Lexmark International | Exhaustion on sale | | Aro Manufacturing v. Convertible Top Replacement | Permissible repair | | Jazz Photo v. International Trade Commission | Refurbishment as repair | | Eastman Kodak v. Image Technical Services | Aftermarket monopolisation | | Verizon Communications v. Trinko | Refusal to deal limits | | Chamberlain Group v. Skylink Technologies | Circumvention nexus | | MDY Industries v. Blizzard Entertainment | 1201(a) distinct from copyright | | Lexmark International v. Static Control | Zone of interests | | eBay v. MercExchange | Injunctive relief standard | | Section 1201 medical device exemptions | Triennial repair exemptions | | Device clearance and approval pathways | Regulatory routes | | Software as a medical device frameworks | Software regulation |

Forms and Templates

The License Agreement Template supplies the structure for a technology or trait licence into a device programme, with the field-of-use and territory provisions a regulated product requires. A development and manufacturing agreement is a separate instrument and should address ownership of process improvements, regulatory file ownership, and what happens to the submission if the relationship ends — three provisions omitted with striking regularity. Clinical study agreements should carry publication timing provisions that give the sponsor a filing window before disclosure, and material transfer agreements for specimens should address downstream ownership of anything developed from them.

Related Toolkits and Checklists

The Patent Fundamentals Toolkit carries the eligibility doctrine that constrains diagnostic claims hardest. The Life Sciences Patent Toolkit covers the adjacent drug regime, whose exclusivity mechanisms devices do not share. The Design Patent Toolkit and the Layered Design Protection Toolkit cover instrument appearance. The Aftermarket, Repair, and Spare Parts IP Toolkit covers consumables and servicing, and the Confidentiality and NDA Toolkit covers the trade secret layer that carries what claims cannot reach.